

Regorafenib (STIVARGA) Criteria for Use Updated May 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive regorafenib.

- Unmanageable Drug-Drug Interaction
- Clinically significant cardiovascular disease [^]
- Pre-existing bleeding diathesis or coagulopathy
- Major surgical procedure within prior 28 days, non-healing wound, ulcer or bone fracture
- Total bilirubin > 1.5 x Upper Limit of Normal (> 6 mg/dL if documented Gilbert's syndrome); ALT and AST > 2 x ULN (> 5 x ULN if due to liver involvement); Alk phos > 2.5 x ULN (> 5 x ULN if due to liver involvement)
- Amylase and lipase > 1.5 x ULN
- GFR \leq 30 mL/min/1.73 m²
- Adequate hematologic parameters: platelet count < 100,000/mm³, hemoglobin \leq 9 mg/dL and ANC < 1500/mm³
- Known pregnancy
- Lactation

[^] Uncontrolled hypertension, unstable or new-onset angina, myocardial infarction within prior 6 months, history of congestive heart failure (New York Heart Association Class 3 or 4)

Inclusion Criteria

All of the following criteria must be met.

- Care is provided by a VA/VA Community care oncology or hematology provider
- Goals of care and role of Palliative Care consult has been discussed and documented
- Eastern Cooperative Oncology Group Performance Status 0 or 1

Additional Inclusion Criteria *One of the following must be met:*

- Metastatic colorectal cancer and prior treatment (or not a candidate) with all of the following: fluoropyrimidine-, oxaliplatin-, irinotecan-based regimens, an anti-VEGF agent and if KRAS wild type, an anti-EGFR agent
- Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) and prior therapy with imatinib and sunitinib (unless contraindicated)
- Hepatocellular carcinoma (HCC) Child-Pugh A, previously treated with sorafenib

Additional Inclusion Criteria *Select if applicable*

- For females who can become pregnant: Pregnancy must be excluded prior to receiving regorafenib
- For females who can become pregnant and males with partners who can become pregnant: counseling provided on potential risks vs. benefits of treatment and the use of effective contraception during pregnancy and for 2 months after stopping treatment

Other justification *if applicable*
